biologics and stuff🧬🧬

[biologics and stuff🧬🧬 @_invaro]

Ok so far 👌

[biologics and stuff🧬🧬 @_invaro]

Let´s use this thread to build the bear case for the Tools space/services $TMO $DHR $WAT $RGEN $WST
I mean industry-wise. Seriously considering sizing up and need to see the other side of the trade at this valuation.
@JerryCap @Borlaug_ @TheTipasa @marc_slans @TheLAPurchaser

[biologics and stuff🧬🧬 @_invaro]

@Jackkk @marcosllorente

[biologics and stuff🧬🧬 @_invaro]

up 40% since then

[biologics and stuff🧬🧬 @_invaro]

$WST $STVN Can we just take a step back and appreciate how market gives 2fks around the Annex 1 opportunity? 90% of the questions on GLPs when they are bakin in something absurd i.e. 10% growth with injectable prices collapsing 70% and generics coming online?

[biologics and stuff🧬🧬 @_invaro]

What happened with the Rales bros? WAKE UP $DHR

[J.P. Reilly @JPReillyMD]

#scai2026 .@SCAI Keynote address on the history and evolution of TAVR. It has become the leading treatment for AS. Now focusing on the long term durability and outcomes.

[biologics and stuff🧬🧬 @_invaro]

@waterboystocks the only thing that is wrong here is $LLY multiple

[biologics and stuff🧬🧬 @_invaro]

@DmytroKrasun The fact that you consider buying it for status is the one and only mistake.

[biologics and stuff🧬🧬 @_invaro]

@HerculeBaditt Assuming those splits are correct, aren’t this tasks already pass through revenue? I mean it would be a topline headwind but not necessarily margin.

[Kontra @KontraInvest]

If oral Wegovy sales are the most exciting part of Q1, gross margin is the most anxiety-inducing.
$NVO

[intern @intern]

gym guys will be like “i can’t believe they took the covid vaccine”

and then inject BPC-157, ipamorelin, MOTS-c, and an unpronounceable peptide shipped from Nicaragua after reading a subreddit comment from liverkingdisciple69 about mice getting jacked

[Jon Oringer @jonoringer]

The NYT just profiled a $1.8B revenue company with 2 employees.

Medvi is a telehealth GLP-1 provider built by Matthew Gallagher, 41, from his house in LA. He launched in September 2024 with $20,000. Here are the numbers:

Month 1: 300 customers
Month 2: 1,300 customers
2025 full year: $401M revenue, 250,000 customers
2026 run rate: $1.8B
Net margin: 16.2% ($65M profit)
Total employees: 2 (him and his brother)
Outside funding: $0

How it works: Medvi is a front end. Two platforms — CareValidate and OpenLoop Health — handle doctors, prescriptions, pharmacies, shipping, and compliance. Gallagher handles brand, website, ads, checkout, and customer service. All built with AI.

His stack: ChatGPT, Claude, and Grok for code. Midjourney and Runway for ad creative. ElevenLabs for voice. Custom AI agents to connect systems. AI chatbot for customer service (which initially hallucinated fake prices he had to honor).

For comparison: Hims & Hers did $2.4B revenue last year with 2,442 employees and 5.5% net margins. Gallagher is running 3x the margin with a fraction of a percent of the headcount.

Back into the unit economics: ~$336M in total costs, probably $160-200M to the telehealth platforms, leaving $130-170M mostly in marketing. Against 250,000 customers, that's a $500-700 CAC. High, but it works because his overhead is virtually zero and LTV at ~$200/month holds up.

He's expanding fast. Men's health launched in February — 50K customers in month one. Meal delivery went live last month. Women's health, hair growth, supplements, and skincare are next.

The vulnerability: zero moat. No proprietary tech, no doctor network, no pharmacy infrastructure. CareValidate or OpenLoop could raise fees or launch competing brands. Anyone could replicate this model in weeks.

Right now, the margins are enormous for anyone who moves fast enough. The question is how long that window stays open.

https://t.co/6bNt5w45Rx

[biologics and stuff🧬🧬 @_invaro]

@fdzmurillo I´ll bet compliance is better on orfo in RoW. Still, orfo COGS is way lower so plenty of room to beat NVO on price.

PD: don´t own any of the GLP-1 manufactures, I believe is a category with massive volume growth, but poor returns given price pressure/competition.

[biologics and stuff🧬🧬 @_invaro]

@fdzmurillo Truth is many people forget/ignores breakfast after taking the pill and keep their morning routine going, so part of that 16.6 is driven by that. If you do orfo with the same requirements I´m pretty sure gap would´ve been smaller.

[biologics and stuff🧬🧬 @_invaro]

@ShanuMathew93 What´s the name of the report? Thx

[The Lancet @TheLancet]

New Editorial—Politicisation of the US FDA: eroding integrity and trust https://t.co/Pd1nBvpli0

[biologics and stuff🧬🧬 @_invaro]

@peter_mantas its a kangaroo stock once it gets to 180s buy zone

[biologics and stuff🧬🧬 @_invaro]

@DeepIceValue none

[biologics and stuff🧬🧬 @_invaro]

GLP1 trade is a PRICE WAR

good luck $NVO $LLY

pharma investing is too hard just KISS

[biologics and stuff🧬🧬 @_invaro]

@ResearchPulse1 so long thesis now it’s 0.4 days without LoE

[Jerry Capital @JerryCap]

we are going to get another inflation shock

800 year war

[biologics and stuff🧬🧬 @_invaro]

Yeah but “nothing ever happens” Brace for impact.

[Vital Knowledge Media @knowledge_vital]

$ECL Ecolab said it would implement a 10-14% energy surcharge effective 4/1 for all its products and services around the world to offset the surge in oil and gas prices